Angiostatic cancer therapy by targeting galectins in the tumor vasculature

ACS Symposium Series

Volumn 1115, Issue , 2012, Pages 233-247

  Schulkens, Iris A ^a   Griffioen, Arjan W ^a   Thijssen, Victor L ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD VESSELS; DIAGNOSIS; DRUG DELIVERY; MICROCIRCULATION; ONCOLOGY;

BLOOD SUPPLY; CANCER THERAPY; DIAGNOSTIC IMAGING; GALECTINS; TARGETED DRUG DELIVERY; TUMOR ANGIOGENESIS; TUMOR VASCULATURE;

TUMORS;

EID: 84894087198     PISSN: 00976156     EISSN: 19475918     Source Type: Book Series    
DOI: 10.1021/bk-2012-1115.ch013     Document Type: Conference Paper

References (76)

1. Carmeliet, P. Mechanisms of angiogenesis and arteriogenesis. Nat. Med. 2000, 6, 389-395.
2. Carmeliet, P. Angiogenesis in life, disease and medicine. Nature 2005, 438, 932-936.
3. Hillen, F.; Griffioen, A. W. Tumour vascularization: Sprouting angiogenesis and beyond. Cancer Metastasis Rev. 2007, 26, 489-502.
4. Griffioen, A. W.; Molema, G. Angiogenesis: Potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol. Rev. 2000, 52, 237-268.
5. Folkman, J.; Cole, P.; Zimmerman, S. Tumor behavior in isolated perfused organs: In vitro growth and metastases of biopsy material in rabbit thyroid and canine intestinal segment. Ann. Surg. 1966, 164, 491-502.
6. Folkman, J. Tumor angiogenesis: Therapeutic implications. N. Engl. J. Med. 1971, 285, 1182-1186.
7. Thijssen, V. L.; Poirier, F.; Baum, L. G.; Griffioen, A. W. Galectins in the tumor endothelium: Opportunities for combined cancer therapy. Blood 2007, 110, 2819-2827.
8. Baum, L. G.; Seilhamer, J. J.; Pang, M.; Levine, W. B.; Beynon, D.; Berliner, J. A. Synthesis of an endogeneous lectin, galectin-1, by human endothelial cells is up-regulated by endothelial cell activation. Glycoconjugate J. 1995, 12, 63-68.
9. Clausse, N.; van den Brule, F.; Waltregny, D.; Garnier, F.; Castronovo, V. Galectin-1 expression in prostate tumor-associated capillary endothelial cells is increased by prostate carcinoma cells and modulates heterotypic cell-cell adhesion. Angiogenesis 1999, 3, 317-325.
10. Lotan, R.; Belloni, P. N.; Tressler, R. J.; Lotan, D.; Xu, X. C.; Nicolson, G. L. Expression of galectins on microvessel endothelial cells and their involvement in tumour cell adhesion. Glycoconjugate J. 1994, 11, 462-468.
11. Ryschich, E.; Lizdenis, P.; Ittrich, C.; Benner, A.; Stahl, S.; Hamann, A.; Schmidt, J.; Knolle, P.; Arnold, B.; Hammerling, G. J.; et al. Molecular fingerprinting and autocrine growth regulation of endothelial cells in a murine model of hepatocellular carcinoma. Cancer Res 2006, 66, 198-211.
12. Thijssen, V. L.; Hulsmans, S.; Griffioen, A. W. The galectin profile of the endothelium; altered expression and localization in activated and tumor endothelial cells. Am. J. Pathol. 2008, 172, 545-553.
13. Thijssen, V. L.; Postel, R.; Brandwijk, R. J.; Dings, R. P.; Nesmelova, I.; Satijn, S.; Verhofstad, N.; Nakabeppu, Y.; Baum, L. G.; Bakkers, J.; et al. Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy. Proc. Natl. Acad. Sci. U.S.A 2006, 103, 15975-15980.
14. Bidon-Wagner, N.; Le Pennec, J. P. Human galectin-8 isoforms and cancer. Glycoconjugate J. 2004, 19, 557-563.
15. Cueni, L. N.; Detmar, M. Galectin-8 interacts with podoplanin and modulates lymphatic endothelial cell functions. Exp. Cell Res. 2009, 315, 1715-1723.
16. Delgado, V. M.; Nugnes, L. G.; Colombo, L. L.; Troncoso, M. F.; Fernandez, M. M.; Malchiodi, E. L.; Frahm, I.; Croci, D. O.; Compagno, D.; Rabinovich, G. A.; et al. Modulation of endothelial cell migration and angiogenesis: A novel function for the "tandem-repeat" lectin galectin-8. FASEB J. 2011, 25, 242-254.
17. Imaizumi, T.; Kumagai, M.; Sasaki, N.; Kurotaki, H.; Mori, F.; Seki, M.; Nishi, N.; Fujimoto, K.; Tanji, K.; Shibata, T. Interferon-{gamma} stimulates the expression of galectin-9 in cultured human endothelial cells. J. Leukoc. Biol. 2002, 72, 486-491.
18. Spitzenberger, F.; Graessler, J.; Schroeder, H. E. Molecular and functional characterization of galectin 9 mRNA isoforms in porcine and human cells and tissues. Biochimie 2001, 83, 851-862.
19. Whitney, P.; Maxwell, S.; Ryan, U.; Massaro, D. Synthesis and binding of lactose-specific lectin by isolated lung cells. Am. J. Physiol. 1985, 248, C258-264.
20. Hsieh, S. H.; Ying, N. W.; Wu, M. H.; Chiang, W. F.; Hsu, C. L.; Wong, T. Y.; Jin, Y. T.; Hong, T. M.; Chen, Y. L. Galectin-1, a novel ligand of neuropilin- 1, activates VEGFR-2 signaling and modulates the migration of vascular endothelial cells. Oncogene 2008, 27, 3746-3753.
21. Gordower, L.; Decaestecker, C.; Kacem, Y.; Lemmers, A.; Gusman, J.; Burchert, M.; Danguy, A.; Gabius, H.; Salmon, I.; Kiss, R.; et al. Galectin-3 and galectin-3-binding site expression in human adult astrocytic tumours and related angiogenesis. Neuropathol. Appl. Neurobiol. 1999, 25, 319-330.
22. Strik, H. M.; Deininger, M. H.; Frank, B.; Schluesener, H. J.; Meyermann, R. Galectin-3: Cellular distribution and correlation with WHO-grade in human gliomas. J. Neurooncol. 2001, 53, 13-20.
23. Deininger, M. H.; Trautmann, K.; Meyermann, R.; Schluesener, H. J. Galectin-3 labeling correlates positively in tumor cells and negatively in endothelial cells with malignancy and poor prognosis in oligodendroglioma patients. Anticancer Res. 2002, 22, 1585-1592.
24. D'Haene, N.; Catteau, X.; Maris, C.; Martin, B.; Salmon, I.; Decaestecker, C. Endothelial hyperplasia and endothelial galectin-3 expression are prognostic factors in primary central nervous system lymphomas. Br. J. Haematol. 2008, 140, 402-410.
25. Garcia-Cardena, G.; Comander, J.; Anderson, K. R.; Blackman, B. R.; Gimbrone, M. A., Jr. Biomechanical activation of vascular endothelium as a determinant of its functional phenotype. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 4478-4485.
26. Rao, S. P.; Wang, Z.; Zuberi, R. I.; Sikora, L.; Bahaie, N. S.; Zuraw, B. L.; Liu, F. T.; Sriramarao, P. Galectin-3 functions as an adhesion molecule to support eosinophil rolling and adhesion under conditions of flow. J. Immunol. 2007, 179, 7800-7807.
27. He, J.; Baum, L. G. Endothelial cell expression of galectin-1 induced by prostate cancer cells inhibits T-cell transendothelial migration. Lab. Invest. 2006, 86, 578-590.
28. van den Brule, F.; Califice, S.; Garnier, F.; Fernandez, P. L.; Berchuck, A.; Castronovo, V. Galectin-1 accumulation in the ovary carcinoma peritumoral stroma is induced by ovary carcinoma cells and affects both cancer cell proliferation and adhesion to laminin-1 and fibronectin. Lab. Invest. 2003, 83, 377-386.
29. Glinskii, O. V.; Turk, J. R.; Pienta, K. J.; Huxley, V. H.; Glinsky, V. V. Evidence of porcine and human endothelium activation by cancer-associated carbohydrates expressed on glycoproteins and tumour cells. J. Physiol. 2004, 554, 89-99.
30. Glinsky, V. V.; Glinsky, G. V.; Rittenhouse-Olson, K.; Huflejt, M. E.; Glinskii, O. V.; Deutscher, S. L.; Quinn, T. P. The role of Thomsen- Friedenreich antigen in adhesion of human breast and prostate cancer cells to the endothelium. Cancer Res. 2001, 61, 4851-4857.
31. Khaldoyanidi, S. K.; Glinsky, V. V.; Sikora, L.; Glinskii, A. B.; Mossine, V. V.; Quinn, T. P.; Glinsky, G. V.; Sriramarao, P. MDA-MB-435 human breast carcinoma cell homo- and heterotypic adhesion under flow conditions is mediated in part by Thomsen-Friedenreich antigen-galectin-3 interactions. J. Biol. Chem. 2003, 278, 4127-4134.
32. Gil, C. D.; La, M.; Perretti, M.; Oliani, S. M. Interaction of human neutrophils with endothelial cells regulates the expression of endogenous proteins annexin 1, galectin-1 and galectin-3. Cell. Biol. Int. 2006.
33. Deo, P.; Glenn, J. V.; Powell, L. A.; Stitt, A. W.; Ames, J. M. Upregulation of oxidative stress markers in human microvascular endothelial cells by complexes of serum albumin and digestion products of glycated casein. J. Biochem. Mol. Toxicol. 2009, 23, 364-372.
34. Stitt, A. W.; He, C.; Vlassara, H. Characterization of the advanced glycation end-product receptor complex in human vascular endothelial cells. Biochem. Biophys. Res. Commun. 1999, 256, 549-556.
35. Imaizumi, T.; Yoshida, H.; Nishi, N.; Sashinami, H.; Nakamura, T.; Hirashima, M.; Ohyama, C.; Itoh, K.; Satoh, K. Double-stranded RNA induces galectin-9 in vascular endothelial cells: Involvement of TLR3, PI3K, and IRF3 pathway. Glycobiology 2007, 17, 12C-15C.
36. Ishikawa, A.; Imaizumi, T.; Yoshida, H.; Nishi, N.; Nakamura, T.; Hirashima, M.; Satoh, K. Double-stranded RNA enhances the expression of galectin-9 in vascular endothelial cells. Immunol. Cell. Biol. 2004, 82, 410-414.
37. Warke, R. V.; Xhaja, K.; Martin, K. J.; Fournier, M. F.; Shaw, S. K.; Brizuela, N.; de Bosch, N.; Lapointe, D.; Ennis, F. A.; Rothman, A. L.; et al. Dengue virus induces novel changes in gene expression of human umbilical vein endothelial cells. J. Virol. 2003, 77, 11822-11832.
38. Alam, S.; Li, H.; Margariti, A.; Martin, D.; Zampetaki, A.; Habi, O.; Cockerill, G.; Hu, Y.; Xu, Q.; Zeng, L. Galectin-9 protein expression in endothelial cells is positively regulated by histone deacetylase 3. J. Biol. Chem. 2011, 286, 44211-44217.
39. Perillo, N. L.; Marcus, M. E.; Baum, L. G. Galectins: Versatile modulators of cell adhesion, cell proliferation, and cell death. J. Mol. Med. 1998, 76, 402-412.
40. Scott, K.; Weinberg, C. Galectin-1: A bifunctional regulator of cellular proliferation. Glycoconjugate J. 2004, 19, 467-477.
41. Hughes, R. C. Galectins as modulators of cell adhesion. Biochimie 2001, 83, 667-676.
42. Paz, A.; Haklai, R.; Elad-Sfadia, G.; Ballan, E.; Kloog, Y. Galectin-1 binds oncogenic H-Ras to mediate Ras membrane anchorage and cell transformation. Oncogene 2001, 20, 7486-7493.
43. Perillo, N. L.; Pace, K. E.; Seilhamer, J. J.; Baum, L. G. Apoptosis of T cells mediated by galectin-1. Nature 1995, 378, 736-739.
44. Park, J. W.; Voss, P. G.; Grabski, S.; Wang, J. L.; Patterson, R. J. Association of galectin-1 and galectin-3 with Gemin4 in complexes containing the SMN protein. Nucleic Acids Res. 2001, 29, 3595-3602.
45. Danguy, A.; Camby, I.; Kiss, R. Galectins and cancer. Biochim. Biophys. Acta 2002, 1572, 285-293.
46. Lefranc, F.; Mathieu, V.; Kiss, R. Galectin-1-mediated biochemical controls of melanoma and glioma aggressive behavior. World J. Biol. Chem. 2011, 2, 193-201.
47. Cooper, D.; Norling, L. V.; Perretti, M. Novel insights into the inhibitory effects of galectin-1 on neutrophil recruitment under flow. J. Leukoc. Biol. 2008, 83, 1459-1466.
48. Norling, L. V.; Sampaio, A. L.; Cooper, D.; Perretti, M. Inhibitory control of endothelial galectin-1 on in vitro and in vivo lymphocyte trafficking. FASEB J. 2008, 22, 682-690.
49. Ito, K.; Scott, S. A.; Cutler, S.; Dong, L. F.; Neuzil, J.; Blanchard, H.; Ralph, S. J. Thiodigalactoside inhibits murine cancers by concurrently blocking effects of galectin-1 on immune dysregulation, angiogenesis and protection against oxidative stress. Angiogenesis 2011, 14, 293-307.
50. Thijssen, V. L.; Barkan, B.; Shoji, H.; Aries, I. M.; Mathieu, V.; Deltour, L.; Hackeng, T. M.; Kiss, R.; Kloog, Y.; Poirier, F. Tumor cells secrete galectin-1 to enhance endothelial cell activity. Cancer Res. 2010, 70, 6216-6224.
51. Wan, S. Y.; Zhang, T. F.; Ding, Y. Galectin-3 enhances proliferation and angiogenesis of endothelial cells differentiated from bone marrow mesenchymal stem cells. Transplant Proc 2011, 43, 3933-3938.
52. Yan, Y. P.; Lang, B. T.; Vemuganti, R.; Dempsey, R. J. Galectin-3 mediates post-ischemic tissue remodeling. Brain Res. 2009, 1288, 116-124.
53. Nangia-Makker, P.; Honjo, Y.; Sarvis, R.; Akahani, S.; Hogan, V.; Pienta, K. J.; Raz, A. Galectin-3 induces endothelial cell morphogenesis and angiogenesis. Am. J. Pathol. 2000, 156, 899-909.
54. Yang, E.; Shim, J. S.; Woo, H. J.; Kim, K. W.; Kwon, H. J. Aminopeptidase N/CD13 induces angiogenesis through interaction with a pro-angiogenic protein, galectin-3. Biochem. Biophys. Res. Commun. 2007, 363, 336-341.
55. Markowska, A. I.; Liu, F. T.; Panjwani, N. Galectin-3 is an important mediator of VEGF- and bFGF-mediated angiogenic response. J. Exp. Med. 2010, 207, 1981-1993.
56. Markowska, A. I.; Jefferies, K. C.; Panjwani, N Galectin-3 protein modulates cell surface expression and activation of vascular endothelial growth factor receptor 2 in human endothelial cells. J. Biol. Chem. 2011, 286, 29913-29921.
57. Eude-Le Parco, I.; Gendronneau, G.; Dang, T.; Delacour, D.; Thijssen, V. L.; Edelmann, W.; Peuchmaur, M.; Poirier, F. Genetic assessment of the importance of galectin-3 in cancer initiation, progression, and dissemination in mice. Glycobiology 2009, 19, 68-75.
58. Fukushi, J.; Makagiansar, I. T.; Stallcup, W. B. NG2 proteoglycan promotes endothelial cell motility and angiogenesis via engagement of galectin-3 and alpha3beta1 integrin. Mol. Biol. Cell 2004, 15, 3580-3590.
59. Rabinovich, G. A.; Cumashi, A.; Bianco, G. A.; Ciavardelli, D.; Iurisci, I.; D'Egidio, M.; Piccolo, E.; Tinari, N.; Nifantiev, N.; Iacobelli, S. Synthetic lactulose amines: Novel class of anticancer agents that induce tumor-cell apoptosis and inhibit galectin-mediated homotypic cell aggregation and endothelial cell morphogenesis. Glycobiology 2006, 16, 210-220.
60. Collins, P. M.; Oberg, C. T.; Leffler, H.; Nilsson, U. J.; Blanchard, H. Taloside inhibitors of galectin-1 and galectin-3. Chem. Biol. Drug Des. 2011, 79, 339-346.
61. Nangia-Makker, P.; Hogan, V.; Honjo, Y.; Baccarini, S.; Tait, L.; Bresalier, R.; Raz, A. Inhibition of human cancer cell growth and metastasis in nude mice by oral intake of modified citrus pectin. J. Natl. Cancer Inst. 2002, 94, 1854-1862.
62. Griffioen, A. W.; van der Schaft, D. W.; Barendsz-Janson, A. F.; Cox, A.; Struijker Boudier, H. A.; Hillen, H. F.; Mayo, K. H. Anginex, a designed peptide that inhibits angiogenesis. Biochem. J. 2001, 354, 233-242.
63. Steege, J. C.; Wagstaff, J.; Mayo, K. H.; Griffioen, A. W. The designer antiangiogenic peptide anginex targets tumor endothelial cells and inhibits tumor growth in animal models. FASEB J. 2002, 16, 1991-1993.
64. Salomonsson, E.; Thijssen, V. L.; Griffioen, A. W.; Nilsson, U. J.; Leffler, H. The anti-angiogenic peptide anginex greatly enhances galectin-1 binding affinity for glycoproteins. J. Biol. Chem. 2011, 286, 13801-13804.
65. Mirandola, L.; Yu, Y.; Chui, K.; Jenkins, M. R.; Cobos, E.; John, C. M.; Chiriva-Internati, M. Galectin-3C inhibits tumor growth and increases the anticancer activity of bortezomib in a murine model of human multiple myeloma. PLoS ONE 2011, 6, e21811.
66. John, C. M.; Leffler, H.; Kahl-Knutsson, B.; Svensson, I.; Jarvis, G. A. Truncated galectin-3 inhibits tumor growth and metastasis in orthotopic nude mouse model of human breast cancer. Clin. Cancer Re.s 2003, 9, 2374-2383.
67. Schirner, M.; Menrad, A.; Stephens, A.; Frenzel, T.; Hauff, P.; Licha, K.; van der Schaft, D. W.; Dings, R. P.; de Lussanet, Q. G.; van Eijk, L. I.; Nap, A. W.; Beets-Tan, R. G.; Bouma-Ter Molecular imaging of tumor angiogenesis. Ann. N. Y. Acad. Sci. 2004, 1014, 67-75.
68. Brandwijk, R. J.; Mulder, W. J.; Nicolay, K.; Mayo, K. H.; Thijssen, V. L.; Griffioen, A. W. Anginex-conjugated liposomes for targeting of angiogenic endothelial cells. Bioconjug. Chem. 2007, 18, 785-790.
69. Kluza, E.; van der Schaft, D. W.; Hautvast, P. A.; Mulder, W. J.; Mayo, K. H.; Griffioen, A. W.; Strijkers, G. J.; Nicolay, K. Synergistic targeting of alphavbeta3 integrin and galectin-1 with heteromultivalent paramagnetic liposomes for combined MR imaging and treatment of angiogenesis. Nano Lett. 2011, 10, 52-58.
70. Dings, R. P.; Van Laar, E. S.; Loren, M.; Webber, J.; Zhang, Y.; Waters, S. J.; Macdonald, J. R.; Mayo, K. H. Inhibiting tumor growth by targeting tumor vasculature with galectin-1 antagonist anginex conjugated to the cytotoxic acylfulvene, 6-hydroxylpropylacylfulvene. Bioconjug. Chem. 2010, 21, 20-27.
71. Johnson, K. D.; Glinskii, O. V.; Mossine, V. V.; Turk, J. R.; Mawhinney, T. P.; Anthony, D. C.; Henry, C. J.; Huxley, V. H.; Glinsky, G. V.; Pienta, K. J.; et al. Galectin-3 as a potential therapeutic target in tumors arising from malignant endothelia. Neoplasia 2007, 9, 662-670.
72. Mathieu, V.; Le Mercier, M.; De Neve, N.; Sauvage, S.; Gras, T.; Roland, I.; Lefranc, F.; Kiss, R. Galectin-1 knockdown increases sensitivity to temozolomide in a B16F10 mouse metastatic melanoma model. J. Invest. Dermatol. 2007, 127, 2399-2410.
73. Le Mercier, M.; Mathieu, V.; Haibe-Kains, B.; Bontempi, G.; Mijatovic, T.; Decaestecker, C.; Kiss, R.; Lefranc, F. Knocking down galectin 1 in human hs683 glioblastoma cells impairs both angiogenesis and endoplasmic reticulum stress responses. J. Neuropathol. Exp. Neurol. 2008, 67, 456-469.
74. Dings, R. P.; Williams, B. W.; Song, C. W.; Griffioen, A. W.; Mayo, K. H.; Griffin, R. J. Anginex synergizes with radiation therapy to inhibit tumor growth by radiosensitizing endothelial cells. Int. J. Cancer 2005.
75. Dings, R. P.; Yokoyama, Y.; Ramakrishnan, S.; Griffioen, A. W.; Mayo, K. H. The designed angiostatic peptide anginex synergistically improves chemotherapy and antiangiogenesis therapy with angiostatin. Cancer Res. 2003, 63, 382-385.
76. Dings, R. P.; Loren, M.; Heun, H.; McNiel, E.; Griffioen, A. W.; Mayo, K. H.; Griffin, R. J. Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization. Clin. Cancer Res. 2007, 13, 3395-3402.